Data Year:

For its 2025 fiscal year, AMPHASTAR PHARMACEUTICLS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Mary Ziping Luo
Chief Operating Officer, Chief Scientist and Chairman
Total Compensation $4,031,078 View details Pay Rank By Title In Biotechnology industry #6 View more
Jack Yongfeng Zhang
Chief Executive Officer, President, Chief Scientific Officer and Director
Total Compensation $8,309,350 View details Pay Rank By Title In Biotechnology industry #146 View more
Rong Zhou
Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd
Total Compensation $2,542,634 View details Pay Rank By Title In Biotechnology industry #99 View more
William J. Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
Total Compensation $3,238,682 View details Pay Rank By Title In Biotechnology industry #130 View more
Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S.
Total Compensation $2,037,856 View details Pay Rank By Title In Biotechnology industry #112 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at AMPHASTAR PHARMACEUTICLS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. AMPHASTAR PHARMACEUTICLS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. AMPHASTAR PHARMACEUTICLS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mary Ziping Luo
Chief Operating Officer, Chief Scientist and Chairman
Total Cash $1,192,043 Equity $2,784,006 Other $55,029 $4,031,078
Jack Yongfeng Zhang
Chief Executive Officer, President, Chief Scientific Officer and Director
Total Cash $1,641,658 Equity $6,604,005 Other $63,687 $8,309,350
Rong Zhou
Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd
Total Cash $1,096,062 Equity $1,403,013 Other $43,559 $2,542,634
William J. Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
Total Cash $1,093,154 Equity $2,088,004 Other $57,524 $3,238,682
Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S.
Total Cash $812,109 Equity $1,184,005 Other $41,742 $2,037,856
For its 2025 fiscal year, AMPHASTAR PHARMACEUTICLS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Jack Yongfeng Zhang CEO Pay $8,309,350 Median Employee Pay $61,658 CEO Pay Ratio 135:1
For its 2025 fiscal year, AMPHASTAR PHARMACEUTICLS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
David Gaugh Total Cash $284,727
Diane Gerst Total Cash $327,750
Floyd F. Petersen Total Cash $325,000
Gayle Deflin Total Cash $340,000
Howard Lee Total Cash $333,500
Michael A. Zasloff Total Cash $331,000
Richard Prins Total Cash $377,500
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.